Eli Lilly and Co (LLY) is Upgraded by Goldman to Buy

Eli Lilly and Co (LLY) was Upgraded by Goldman to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. Goldman advised their investors in a research report released on Sep 27, 2016.

Many Wall Street Analysts have commented on Eli Lilly and Co. Eli Lilly and Co was Upgraded by JP Morgan to ” Overweight” on Sep 8, 2016.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Co opened for trading at $81.05 and hit $81.46 on the upside on Thursday, eventually ending the session at $81.29, with a gain of 0.52% or 0.42 points. The heightened volatility saw the trading volume jump to 26,39,754 shares. Company has a market cap of $89,731 M.

In a different news, on Aug 17, 2016, Jackson P Tai (director) purchased 5,773 shares at $80.31 per share price. According to the SEC, on Jul 29, 2016, Donald A Zakrowski (Chief Accounting Officer) sold 1,213 shares at $83.16 per share price. On Jun 13, 2016, Melissa S Barnes (Chief Eth/Cmpl Ofcr & SVP, ERM) sold 992 shares at $73.77 per share price, according to the Form-4 filing with the securities and exchange commission.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Eli Lilly and Co

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.